Complex processes, scattered production units, need for more safety zones and shortage of skilled staffers are some of the top reasons that restricted Bharat Biotech?s Covaxin from becoming the poster-boy of India?s vaccination story against Covid-19. Read More

reported by Himani Chandna at News18